Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 24Colorectal Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Gallbladder Neoplasms 3Esophageal Neoplasms 3HER2-positive Gastric Cancer 2Cholangiocarcinoma 2Stage IA Pancreatic Adenocarcinoma 1Recurrence 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1

Interventions

Drug Therapy 3Radiotherapy 2uridine triacetate 1camrelizumab 1bismuth tripotassium dicitrate 1Telbivudine 1Tegafur 1Surgical Procedures, Operative 1Pharmaceutical Services 1Ofloxacin 1Octreotide 1Metronidazole 1Levofloxacin 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1Fluorouracil 1Fecal Microbiota Transplantation 1Esomeprazole 1Docetaxel 1Dihydrouracil Dehydrogenase (NADP) 1Clarithromycin 1Cisplatin 1Celecoxib 1Capecitabine 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Tegafur × Gastrointestinal × Clear all
NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Chang Gung Memorial Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡